Law360, New York (May 05, 2010, 3:32 PM ET) -- Aiming to expand its product offerings, C.R. Bard Inc. announced Wednesday that it would buy breast cancer medical device maker SenoRx Inc. in an all-stock deal worth roughly $213 million.
The Murray Hill, N.J.-based medical technology manufacturer said it would pay $11 per share, or $213 million in the aggregate, to acquire SenoRx — a premium of roughly 14 percent over the stock price as of Tuesday and 41 percent over the company's average stock price over the past 90 days.
"Our agreement with Bard represents...
Weil, Wilson Advise On $213M Bard, SenoRx Merger
To view the full article, take a free trial now.
